Novavax, Inc. (NVAX)
NASDAQ: NVAX · Real-Time Price · USD
10.80
+0.02 (0.14%)
Nov 9, 2026, 10:55 AM EST - Market open
Novavax Revenue
Novavax had revenue of $68.30M in the quarter ending September 30, 2026, a decrease of -3.05%. This brings the company's total for the last twelve months to $411.65M, down -61.33% year-over-year. In the year 2025, Novavax had annual revenue of $1.12B with 64.69% growth. That makes Novavax the 12,417th largest company in the world by revenue and 2,414th in the United States.
Revenue (ttm)
$411.65M
Revenue Growth
-61.33%
P/S Ratio
4.32
Revenue / Employee
$549,598
Employees
749
Market Cap
1.78B
Revenue by Geography
- Rest of North America 575.67M 51.2%
- United States 405.61M 36.1%
- Rest of The World 126.46M 11.3%
- Europe 15.74M 1.4%
Fiscal year ended Dec 31, 2025 See the full Novavax breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.12B | 441.32M | 64.69% |
| Dec 31, 2024 | 682.16M | -301.54M | -30.65% |
| Dec 31, 2023 | 983.71M | -998.17M | -50.36% |
| Dec 31, 2022 | 1.98B | 835.58M | 72.89% |
| Dec 31, 2021 | 1.15B | 670.69M | 141.02% |
| Dec 31, 2020 | 475.60M | 456.94M | 2,448.48% |
| Dec 31, 2019 | 18.66M | -15.63M | -45.57% |
| Dec 31, 2018 | 34.29M | 3.11M | 9.98% |
| Dec 31, 2017 | 31.18M | 15.82M | 103.06% |
| Dec 31, 2016 | 15.35M | -20.90M | -57.65% |
| Dec 31, 2015 | 36.25M | 5.59M | 18.24% |
| Dec 31, 2014 | 30.66M | 9.74M | 46.59% |
| Dec 31, 2013 | 20.92M | -1.16M | -5.26% |
| Dec 31, 2012 | 22.08M | 7.39M | 50.30% |
| Dec 31, 2011 | 14.69M | 14.35M | 4,182.22% |
| Dec 31, 2010 | 343.00K | 18.00K | 5.54% |
| Dec 31, 2009 | 325.00K | -739.00K | -69.45% |
| Dec 31, 2008 | 1.06M | -449.00K | -29.68% |
| Dec 31, 2007 | 1.51M | -225.00K | -12.95% |
| Dec 31, 2006 | 1.74M | -3.61M | -67.47% |
| Dec 31, 2005 | 5.34M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 1.96B |
| Agios Pharmaceuticals | 140.84M |
| Mesoblast | 120.25M |
| Stoke Therapeutics | 28.21M |
| Generate Biomedicines | 26.48M |
| Maze Therapeutics | 20.00M |
| Zenas BioPharma | 11.00M |
| Lycia Therapeutics | 4.44M |
NVAX News
- 3 days ago - Novavax price target lowered to $16 from $18 at B. Riley - TheFly
- 3 days ago - Novavax price target lowered to $7 from $8 at BofA - TheFly
- 4 days ago - Novavax Earnings Call Transcript: Q3 2026 - Transcripts
- 4 days ago - Novavax Earnings release: Q3 2026 - Filings
- 4 days ago - Novavax Slides: Q3 2026 - Filings
- 4 days ago - Novavax Quarterly report: Q3 2026 - Filings
- 4 days ago - Novavax raises FY26 adjusted revenue view to $385M-$415M from $235M-$275M - TheFly
- 4 days ago - Novavax reports Q3 EPS (19c), consensus (42c) - TheFly